NASDAQ:VCEL Vericel (VCEL) Stock Price, News & Analysis $46.71 +1.39 (+3.07%) Closing price 04:00 PM EasternExtended Trading$45.69 -1.02 (-2.18%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vericel Stock (NASDAQ:VCEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vericel alerts:Sign Up Key Stats Today's Range$45.79▼$47.0050-Day Range$32.82▼$48.3152-Week Range$28.95▼$48.75Volume433,573 shsAverage Volume488,453 shsMarket Capitalization$2.39 billionP/E Ratio111.22Dividend YieldN/APrice Target$57.00Consensus RatingHold Company Overview Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues. Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients. EPICEL® (cultured epidermal autograft) is approved for use in pediatric burn patients with deep partial-thickness or full-thickness burns covering at least 30% of total body surface area. Vericel manages the entire manufacturing process—from cell collection and expansion to final product release—at its state-of-the-art cell processing facilities in the United States. The company distributes its products across the U.S. market and has established licensing and distribution partnerships to serve patients in select international regions, including Europe, Canada and Australia. Beyond its commercial portfolio, Vericel maintains a pipeline of investigational therapies targeting tendon repair and other musculoskeletal injuries. Its research and development efforts leverage proprietary cell culture platforms and delivery technologies aimed at addressing significant unmet medical needs in regenerative medicine.AI Generated. May Contain Errors. Read More Vericel Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreVCEL MarketRank™: Vericel scored higher than 68% of companies evaluated by MarketBeat, and ranked 242nd out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingVericel has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialVericel has a consensus price target of $57.00, representing about 22.0% upside from its current price of $46.71.Amount of Analyst CoverageVericel has only been the subject of 3 research reports in the past 90 days.Read more about Vericel's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth71.43% Earnings GrowthEarnings for Vericel are expected to grow by 71.43% in the coming year, from $0.49 to $0.84 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is 111.22, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 43.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is 111.22, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.42.Price to Book Value per Share RatioVericel has a P/B Ratio of 6.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vericel's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.75% of the float of Vericel has been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 9.05.Change versus previous monthShort interest in Vericel has recently decreased by 6.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.49 News SentimentVericel has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vericel this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for VCEL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vericel to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,084,167.00 in company stock.Percentage Held by Insiders7.60% of the stock of Vericel is held by insiders.Percentage Held by InstitutionsVericel has minimal institutional ownership at this time.Read more about Vericel's insider trading history. Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VCEL Stock News HeadlinesVericel CorpJuly 24, 2026 | money.usnews.comVericel (NASDAQ:VCEL) Raised to "Buy" at Wall Street ZenJuly 18, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.July 28 at 1:00 AM | Profits Run (Ad)Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026July 16, 2026 | globenewswire.comVericel Stock Short Interest Report | NASDAQ:VCEL | BenzingaJuly 13, 2026 | benzinga.comVericel (NASDAQ:VCEL) Insider Sells 2,732 Shares of StockJuly 1, 2026 | insidertrades.comVericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really SuggestsJune 27, 2026 | fool.comVericel CorporationJune 9, 2026 | edition.cnn.comSee More Headlines VCEL Stock Analysis - Frequently Asked Questions How have VCEL shares performed this year? Vericel's stock was trading at $36.01 at the beginning of the year. Since then, VCEL stock has increased by 29.7% and is now trading at $46.71. How were Vericel's earnings last quarter? Vericel Corporation (NASDAQ:VCEL) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. The firm's quarterly revenue was up 30.1% on a year-over-year basis. Read the conference call transcript. Who are Vericel's major shareholders? Top institutional investors of Vericel include Kopp Family Office LLC (0.10%), Handelsbanken Fonder AB (0.05%), Versant Capital Management Inc (0.01%) and GAMMA Investing LLC. Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Paul K Wotton, Robert L Md Zerbe, Joseph Anthony Mara Jr, Steven C Gilman, Sean C Flynn, Michael Halpin and Jonathan Siegal. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Palo Alto Networks (PANW) and Netflix (NFLX). Company Calendar Last Earnings5/07/2026Today7/28/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 VCEL's financial health is in the Green zone, according to TradeSmith. VCEL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VCEL CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees300Year Founded1989Price Target and Rating Average Price Target for Vericel$57.00 High Price Target$70.00 Low Price Target$46.00 Potential Upside/Downside+22.0%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.42 Trailing P/E Ratio111.22 Forward P/E Ratio95.33 P/E GrowthN/ANet Income$16.52 million Net Margins7.35% Pretax Margin7.64% Return on Equity6.41% Return on Assets4.61% Debt Debt-to-Equity RatioN/A Current Ratio5.18 Quick Ratio4.79 Sales & Book Value Annual Sales$276.26 million Price / Sales8.63 Cash Flow$0.57 per share Price / Cash Flow81.58 Book Value$7.01 per share Price / Book6.66Miscellaneous Outstanding Shares51,070,000Free Float47,187,000Market Cap$2.39 billion OptionableOptionable Beta1.07 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:VCEL) was last updated on 7/28/2026 by MarketBeat.com Staff. From Our PartnersPrepare Now For Elon Musk's "A.R.M."Elon Musk has already reshaped industries with PayPal, Tesla, and SpaceX. Now he is teasing something he calls...Paradigm Press | SponsoredALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | SponsoredTrump is positioned. Elon lights the fuse.Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...Crypto 101 Media | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
